Leech Tishman Nelson Hardiman is a leading authoritative voice in the rapidly expanding biologics industry. We navigate the regulatory, intellectual property, and business challenges within the biologics industry, which affect many of the most promising developing treatments for cancer and other major diseases. Our focus on healthcare innovation magnifies our understanding of biologics and the costly technologies and manufacturing techniques needed to produce and market biologic treatments.
Our experience with the biologic regulatory pathways developed and outlined by the Biologics Price Competition and Innovation Act (BPCIA), as well as FDA, state, and local regulations, allows us to assist clients with these complex legal issues. We have a keen understanding of regulatory compliance and innovative healthcare finance, as well as a commitment to revolutionize the battle against major diseases.
- Advised on early round capital raising for startups and all manner of healthcare finance issues for entrepreneurial ventures
- Advised on business plan development and regulatory issues and structured health technology business models to comply with healthcare laws and regulations
- Documented significant domestic and international IP licensing, manufacturing, marketing, and distribution agreements for biologics and related products
- Evaluated a biotechnology company’s marketing campaign for compliance with the federal Anti-Kickback statute and other fraud and abuse laws
- Counseled companies in clinical trials, technology start-ups, and other organizations on HIPAA, state health information privacy laws, and the development of privacy compliance programs
- Advised pharmaceutical and manufacturing clients on all regulatory aspects of healthcare